Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trials Face More FDA Scrutiny; DoJ Settlements Focus On Data Use

Executive Summary

FDA is ratcheting up enforcement of clinical trial sites, conducting more inspections during the course of pivotal studies and issuing more warning letters to investigators.

You may also be interested in...



J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe

The government charged J&J with bribing doctors in Greece, Poland and Romania to order or prescribe its products; the $70 million settlement includes a deferred prosecution agreement.

Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection

Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S

AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel